Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Science

Share Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Sign up to save your podcasts

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

More shows like PeerVoice Oncology & Haematology Video

PeerVoice Oncology & Haematology Audio

PeerVoice Heart & Lung Audio

PeerVoice Endocrinology & Metabolic Disorders Audio

PeerVoice Digestive Diseases Audio

PeerVoice Digestive Diseases Video

PeerVoice Immunology & Infectious Disease Video

PeerVoice Immunology & Infectious Disease Audio

PeerVoice Internal Medicine Audio

PeerVoice Internal Medicine Video

The Uromigos

Oncology Brothers: Practice-Changing Cancer Discussions